Home Companies Catalysts Deep Dives
Bizengri zenocutuzumab-zbco APPROVED
Drug Profile
ModalityBispecific antibody
RouteIV
Therapy AreaOncology
Launch2024-12-04
Peak Sales Est$500M
Formulations[{"id":"bizengri-iv","route":"IV","setting":"OUTPATIENT","frequency":"Weekly (loading) then Q2W","is
Companies
GMAB (LICENSEE)100%
Mechanism: Anti-HER2/HER3 bispecific (NRG1 fusion blocker)
Expert: Bispecific antibody targeting HER2 and HER3. Blocks NRG1 fusion-mediated signaling by preventing HER2:HER3 heterodimerization, shutting down oncogenic PI3K/AKT pathway activation driven by NRG1 gene fusions.
Everyday: Blocks a faulty growth signal (NRG1 fusion) that tells cancer cells to grow. Like cutting a phone line that is constantly telling cells to multiply.
Targets: []
Programs (2)
IndicationStageKey StudyRegional Status
NRG1+ NSCLCAPPROVEDeNRGy[{"notes":"Accelerated approval","stage":"APPROVED","region":"US","approval_date
NRG1+ PDACAPPROVEDeNRGy[{"notes":"Accelerated approval","stage":"APPROVED","region":"US","approval_date
Notes
First systemic therapy targeting NRG1 fusion-positive cancers. Approved via accelerated approval based on eNRGy study. Added to Genmab portfolio via $8B Merus acquisition (Sep 2025). Also has Breakthrough Therapy designation for NRG1+ cholangiocarcinoma.
Data from Supabase · Updated 2026-03-24